The Hong Kong Polytechnic University
Hong Kong
NCT Number: NCT01976832
This study intends to use music and movement (MWM) to reduce anxiety and behavioral symptoms of people with early dementia (PWD) and their family carers in the community. It also aims to examine whether MWM can enhance the sleep quality of PWD and their family caregivers and promote their well-being.
This is a mixed methods study with the quantitative paradigm being the main research approached used. The quantitative arm will be a randomized controlled trial (RCT). The qualitative arm will adopt a naturalistic approach through interviewing for data collection. Recruited subjects from the community centres of non-government organizations (NGOs) will be randomly allocated to the intervention and control group.
The outcome measures of the PWD will include Rating Anxiety in Dementia (RAID), Geriatric Depression Scale (GDS), Neuropsychiatric Inventory Questionnaire (NPI-Q), Pittsburgh Sleep Quality Index (PQSI), Quality of Life - Alzheimer's Disease (QOL-AD), Mini-Mental State Examination (MMSE), Revised Life Event Scale (RLES), Modified Brathel Index (MBI) and Non-pharmacological Therapy Experience Scale (NPTES), whereas the outcome measures of the family caregivers will be Patient Health Questionnaire 9 (PHQ-9), Generalized Anxiety Disorder 7 (GAD-7), Zarit Burden Scale (ZBD), Pittsburgh Sleep Quality Index (PSQI), Reverse Life event Scale (RLES), and World Health Organization Quality of Life-BREF (WHOQOL-BREF).
To address the research questions, data will be collected at baseline (T0), immediately post-intervention at 8-weeks (T1), and 8 post-intervention (T2). The qualitative arm of this study will contribute to the understanding of issues and effects of MWM as an intervention. Its finding will complement the results obtained from the RCT.
Looking for future studies?
Notify Me65 year and older
All sexes
Interventional
Not applicable
Hong Kong
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants in the intervention group will receive the intervention delivered by their family member according to the validated 8-week music with movement (MWM) intervention protocol.
The control group will receive a protocol for social interaction as the control condition, where caregivers were asked to discuss up to date news with PWeD.
The design of the control condition will be highly similar to the MWM protocol in terms of the frequency and duration of the sessions, the number of people involved, and the total intervention period.
Time frame: At baseline (T0), immediately post-intervention at 8-weeks (T1), and 8-weeks post-intervention (T2)
For PWD only
Comparisons of changes of RAID will be considered as follows:
Time frame: At baseline (T0), immediately post-intervention at 8-weeks (T1), and 8-weeks post-intervention (T2)
For PWD only
Comparisons of changes of RAID will be considered as follows:
Time frame: At baseline (T0), immediately post-intervention at 8-weeks (T1), and 8-weeks post-intervention (T2)
For PWD only
Comparisons of changes of RAID will be considered as follows:
Time frame: At baseline (T0), immediately post-intervention at 8-weeks (T1), and 8-weeks post-intervention (T2)
For PWD and Caregivers of PWD only
Comparisons of changes of RAID will be considered as follows:
Time frame: At baseline (T0), immediately post-intervention at 8-weeks (T1), and 8-weeks post-intervention (T2)
For PWD only
Comparisons of changes of RAID will be considered as follows:
Time frame: At baseline (T0), immediately post-intervention at 8-weeks (T1), and 8-weeks post-intervention (T2)
For Caregivers of PWD only
Comparisons of changes of RAID will be considered as follows:
Time frame: At baseline (T0), immediately post-intervention at 8-weeks (T1), and 8-weeks post-intervention (T2)
For Caregivers of PWD only
Comparisons of changes of RAID will be considered as follows:
Time frame: At baseline (T0), immediately post-intervention at 8-weeks (T1), and 8-weeks post-intervention (T2)
For Caregivers of PWD only
Comparisons of changes of RAID will be considered as follows:
Time frame: At baseline (T0), immediately post-intervention at 8-weeks (T1), and 8-weeks post-intervention (T2)
For Caregivers of PWD only
Comparisons of changes of RAID will be considered as follows:
Time frame: At baseline (T0), immediately post-intervention at 8-weeks (T1), and 8-weeks post-intervention (T2)
For PWD only
Comparisons of changes of RAID will be considered as follows:
Time frame: At baseline (T0), immediately post-intervention at 8-weeks (T1), and 8-weeks post-intervention (T2)
For PWD and Caregivers of PWD
Comparisons of changes of RAID will be considered as follows:
Time frame: At baseline (T0), immediately post-intervention at 8-weeks (T1), and 8-weeks post-intervention (T2)
For PWD only
Comparisons of changes of RAID will be considered as follows:
Time frame: At baseline (T0), immediately post-intervention at 8-weeks (T1), and 8-weeks post-intervention (T2)
For PWD only
Comparisons of changes of RAID will be considered as follows:
Time frame: once per month within the intervention period
NPTES will be collected within the intervention period on several occasions. That is to say, to be obtained once per month between T0 to T1, and only for the intervention group. It is an observational tool intended for capturing the qualitative information during an intervention.
The Hong Kong Polytechnic University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04786561
Alzheimer Disease, Anxiety
Tønsberg, Norway
View Trial DetailsNCT02742597
Alzheimer Disease, Alzheimer's Disease
London, Ontario, Canada
View Trial DetailsNCT02789800
Alzheimer Disease, Alzheimer's Disease
Chicoutimi, Quebec, Canada
View Trial DetailsNCT02697435
Anxiety, Anxiety Disorders
Pittsburgh, Pennsylvania, United States
View Trial Details